August 18, 2025

NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark this link for your convenience.

PSC Launches New Monthly Series "Discuss With Us"

The NRG Oncology Protocol Support Committee (PSC) is excited to introduce their new Discuss With Us series. The sessions will take place via zoom on the third Wednesday of every month at 2 pm ET for one hour.

Learn more on our

"Discuss With Us" webpage

ACTIVATION

GENITOURINARY

NRG-GU015: Activation Date: August 14, 2025, posted on CTSU.

TERMINATIONS

GYNECOLOGIC

NRG-GY003: Terminated effective July 26, 2025; version date June 2, 2020 (posted on NRG Oncology)

NRG-GY007: Terminated effective August 3, 2025; version date February 28, 2020 (posted on NRG Oncology)

OTHER PROTOCOL NOTICES

1. ALL DISEASE SITES

NRG-GY022: Reminder: Actively Recruiting MALE Patients only Read More

2. BIOSPECIMEN BANK

Kit Shipments to Sites in Canada

Important information re: shipments of kits from BB Columbus to Sites in Canada. Please see the memorandum, dated August 18, 2025, posted on CTSU.

Printing Biospecimen Transmittal PDFs from Rave

Please note an effort is underway to clarify how to obtain a Biospecimen Transmittal PDF for submission to the NRG Oncology Biospecimen Bank. Read More

3. BRAIN

NRG-BN011: For all new and current participants receiving Lomustine in the US, orders should be directed to Azurity Pharmaceuticals. A Patient Assistance Program (PAP) form will need to be completed for each participant. Please see the memo posted on CTSU for further details.

NRG-BN011: The central lab, NYU Langone, will be closed on Monday September 1, 2025, for Labor Day. Please plan tissue shipments accordingly. 

4. BREAST

NRG-BR009/OFSET: Site-Directed Video Tools

5. GASTROINTESTINAL

NRG-GI006: Spanish Translated consent form, dated July 02, 2025, posted on CTSU.

6. GENITOURINARY

NRG-GU014: Updated Biospecimen Manual, dated August 11, 2025, posted on CTSU.

NRG-GU011: Reminder! This phase II trial for patients with Oligometastatic Prostate Cancer is open to enrollment. The study is open to all NCTN member sites in the U.S and Canada. Please help us enroll. Protocol documents are posted on CTSU.

7. GYNECOLOGIC

NRG-GY026: Reminder! Now accruing patients of all stages and all histologic subtypes of endometrial cancer.

NRG-GY031: Please note, there is an error in the section 4.2 table and the Biospecimen Collection and Submission Manual. The Part I PK collection is to be done on Cycle 1, Day 1, and Cycle 1, Day 8. This will be updated with the next amendment.

8. HEAD & NECK

NRG-HN008 - Reminder: please update treatment and AE data weekly. This is a Phase I trial and timely data submission is very important. 

9. VTOC TRAINING

The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on NRG-BN014, NRG-BR009, NRG-CC005, NRG-CC011, NRG-CC013, NRG-CC014, NRG-CC015, NRG-GU015 and NRG-HN014. Space is limited so register now and reserve your seat. The next webinar training is scheduled for September 10, 2025.

Investigator Brochure (IB) updates have been issued for the following studies:

*The current version of the Investigator Brochure Documents for Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI)-sponsored trials are available for access via the Cancer Therapy Evaluation Program (CTEP) Agent Inventory Management System (AURORA) application. Log-in using your Identity and Access Management (IAM) or ID.me credentials and provide the requested information to access the document.

Every site principal investigator is responsible for reviewing this document. The Investigator Brochure is for use by the site principal investigator and any study personnel under his/her supervision who need to know the contents for the conduct of a clinical trial, including Institutional Review Board(s) or Independent Ethics Committee(s).

1. NRG Oncology Currents Newsletter

The August issue of the NRG Currents eNewsletter is now available. See this month's protocol news, NRG Oncology Podcast episodes, FORTE Study updates, Advocate Angle and PSC columns, and more! Read the August Newsletter here. 

2. Labor Day Holiday Closures

Please refer to the memorandum posted on CTSU for information about NRG Oncology Operations offices, SDMCs, Biospecimen Banks, and McKesson Research Services closures and shipping information for the upcoming Labor Day holiday on Monday, September 1, 2025.

5. PRESS RELEASE: Dual Immune Checkpoint Inhibition with Radiotherapy does not Improve Progression-Free Survival for Patients with Newly Diagnosed MGMT-unmethylated Glioblastoma

NRG Oncology recently reported the results of the National Cancer Institute sponsored phase II/III NRG-BN007 clinical trial showing that combining ipilimumab and nivolumab with radiation therapy (RT) did not improve progression-free survival (PFS) for patients with newly diagnosed MGMT-unmethylated (uMGMT) glioblastoma in comparison to standard RT with temozolomide (TMZ). Accordingly, this trial will not progress to a phase III. These results were recently published in the Journal of Clinical Oncology. Read the press release

6. PRESS RELEASE: NRG Oncology Appoints New NCORP and Veteran Affairs Research Leadership

NRG Oncology (NRG), a National Cancer Institute (NCI) National Clinical Trials Network (NCTN) group focused on improving outcomes for adults with cancer through multi-center clinical research, recently announced new Deputy NRG NCI Community Oncology Research Program (NCORP) Chair and Vice Chair of the NRG Veteran Affairs & Military Treatment Facility (VA-MTF) Subcommittee. Read the press release

7. PRESS RELEASE: NRG Oncology Opens New “ARCHER” Clinical Trial (NRG-GU015) Testing a Shorter Treatment Duration of Radiation Therapy for Muscle Invasive Bladder Cancer

NRG Oncology (NRG), a National Cancer Institute (NCI) National Clinical Trials Network (NCTN) group focused on improving outcomes for adult cancers, recently opened a new clinical trial, “ARCHER” (NRG-GU015), to study a shorter duration of radiation therapy for patients with muscle invasive bladder cancer. Read the press release

8. NRG Health Care Access Fellowship – Call for applications

NRG Oncology is currently seeking applications for the NRG Care Access Fellowship. This program trains selected early-stage investigators in the NRG Oncology system by means of a structured mentorship experience, with particular emphasis given to the recruitment of researchers with a passion for improving health care access. Our vision is to have at least one scholar for every disease site we study. The deadline for applications is September 19, 2025, and awards will be announced in November. Additional information about the program is posted on NRG Oncology. Fellowship Start Date: January 1, 2026

9. RFA for medical oncologist Vice Chair, NRG Oncology Head and Neck Cancer Committee

Applications DUE September 1, 2025 - Read more and how to apply

10. RFA for medical oncologist VICE Chair, NRG Oncology Lung Cancer Committee

Applications DUE September 1, 2025 - Read more and how to apply

11. NRG Member Information Form

We are excited to introduce the NRG Member Information Data Collection Initiative that will allow us to create a comprehensive member database, enabling us to better understand and serve our members. Your information will be kept secure and confidential, ensuring that your privacy is always protected. All members are encouraged to complete the form or indicate that they wish to opt out of this data collection initiative. 

Scan the QR code below or click this link to access the form. 

Questions? Read more here

Any manuscript or abstract resulting from research conducted under the auspices of our NCI grant awards must be processed through the NRG Publications Office before being submitted to the journal or association. Please reach out to NRG-Publications@NRGOncology.org as a first step to ensure all requirements are met.

NRG Oncology is pleased to report the scientific articles that appeared during the previous week. 

PUBLISHED ARTICLES

Gondi V, Pugh SL, Mehta MP, Wefel JS, Tomé WA, Sun AY, Grecula J, Redmond KJ, Fogh S, Gaspar L, Konski A, Bovi J, Robinson CG, Corn B, Videtic GM, Lok BH, Yoon HA, Heinzerling JH, DeNittis AS, McGarry RC, Devisetty K, Kundapur V, Wu AJ, McCarron EC, Thibault I, Simon EL, Baschnagel AM, Narayan S, Pollock J, Paulus R, Kachnic LA; NRG Oncology. Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients with Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003. J Clin Oncol. 2025 Aug 11:JCO2500221. doi: 10.1200/JCO-25-00221. Epub ahead of print. PMID: 40789106; PMCID: PMC12342643. Read more

Lassman AB, Polley MC, Iwamoto FM, Sloan AE, Wang TJC, Aldape KD, Wefel JS, Gondi V, Gutierrez AN, Manasawala MH, Gilbert MR, Sulman EP, Wolchok JD, Green RM, Neil EC, Lukas RV, Goldlust SA, Snuderl M, Galbraith K, Dignam JJ, Won M, Mehta MP. Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial. J Clin Oncol. 2025 Aug 8:JCO2500618. doi: 10.1200/JCO-25-00618. Epub ahead of print. PMID: 40779733. Read more

ACCEPTED ABSTRACTS

Movsas B, Hu C, Higgins KA, Ross HJ, Jabbour SK, Kozono DE, Owonikoko TK, Xiao C, Shoji T, Faller BA, Mohindra P, Dib EG, Brownstein JM, Chun SG, Kuzma CS, Kotecha RR, Onitilo AA, Paulus R, Bradley JD, Bruner DW. Comprehensive Patient Reported Outcomes (PROs) from NRG LU005: A Randomized Trial of Chemoradiation (CRT) +/- Atezolizumab In Limited-Stage Small Cell Lung Cancer (LS-SCLC). ASTRO (American Society for Radiation Oncology). Late Breaking Abstr LBA 08.

Roach M III, Karrison T, Chung H, Chang AJ, Gomella LG, Hsu I, Morton G, Wallace RE, Movsas B, Watkins Bruner D, Dicker AP, Citrin D, Kaufman I, Michalski JM, Vigneault E, Papagikos MA, Spratt DE, Jani AB, Johnson T, Sandler HM. Androgen Deprivation Therapy (ADT) and High Dose Definitive Radiotherapy (RT) +/- Whole Pelvic RT in Patients with Unfavorable Intermediate or Favorable High-Risk Prostate Cancer: Early Results of a Phase III Randomized Controlled Trial. ASTRO (American Society for Radiation Oncology). Late Breaking Abstract.

Spratt DE, Karrison TG, Sandler HM, Posadas EM, Chen R, Wallace RE, Monroe JI, Gomella L, Dess RT, Vassil A, Ebacher A, Gunter T, Lee RJ, DiNome J, Delacroix SE Jr., Michalski JM, Shen X, Johnson T, Nguyen PL, Feng FY. A Double-Blinded Placebo-Controlled Biomarker Stratified Randomized Trial of Apalutamide (APA) and Radiotherapy for Recurrent Prostate Cancer (NRG GU006, BALANCE trial). ASTRO (American Society for Radiation Oncology). Oral Presentation

Please note the following upcoming meetings and abstract submission deadlines

UPCOMING MEETINGS:

AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Sep 18-21, 2025; Baltimore, MD

American Society for Radiation Oncology (ASTRO); Sep 28-Oct 1, 2025; San Francisco, CA

Canadian Association of Radiation Oncology (CARO); Sep 10-13, 2025; Calgary, AB

PA Breast Cancer Coalition (PBCC); Oct 15, 2025; Harrisburg, PA

International Society for Quality-of-Life Research (ISOQOL); Oct 22-25, 2025; Milwaukee, WI

Radiological Society of North America (RSNA); Nov 30-Dec 4, 2025; Chicago, IL

Society for Immunotherapy of Cancer (SITC); Nov 5-9, 2025; National Harbor, MD

UPCOMING ABSTRACT SUBMISSION DEADLINES:

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; Oct 22-26, 2025; Boston, MA; LBA and Clinical Trials Sep 10, 2025, 1:00 pm ET

American Society of Clinical Oncology (ASCO) GI; Jan 8-10, 2026; San Francisco, CA; Due to publications committee Aug 26, 2025; Submission deadline Sep 9, 2025, 11:59 pm ET; LBA Oct 9, 2025, 12:00 pm ET

American Society of Colon and Rectal Surgeons (ASCRS); May 9-12, 2026; Tampa, FL; Due to publications committee Sep 30, 2025; Submission deadline Oct 14, 2025, 11:59 pm ET; LBA / Clinical Trials Jan 28, 2026

European Society for Medical Oncology (ESMO); Oct 17-21, 2025; Berlin, Germany; LBA Sep 9, 2025, 21:00 CET (placeholder required)

European Society of Gynaecological Oncology (ESGO); Feb 26-Mar 1, 2026; Copenhagen, Denmark; Due to publications committee Oct 17, 2025; Submission deadline Oct 31, 2025, 23:59 CET; LBA Jan 15, 2026

European Society for Radiotherapy and Oncology (ESTRO); May 15-19, 2026; Stockholm, Sweden; Due to publications committee Oct 29, 2025; Submission deadline Nov 12, 2025; LBA Apr 8, 2026

International Gynecologic Cancer Society (IGCS); Nov 5-7, 2025; Cape Town, South Africa; LBA Sep 29, 2025 (placeholder required)

San Antonio Breast Cancer Symposium (SABCS); Dec 9-12, 2025; San Antonio, TX; LBA Sep 30, 2025, 11:59 pm CT

Society for Neuro-Oncology (SNO); Nov 19-23, 2025; Honolulu, HI; LBA Sep 2, 2025, 5:00 pm ET

Society of Surgical Oncology (SSO) - Advanced Cancer Therapies; Feb 14-16, 2026; Fort Lauderdale, FL; Due to publications committee Oct 6, 2025; Submission deadline Oct 20, 2025

Society of Urologic Oncology (SUO); Dec 2-5, 2025; Dallas, TX; Submission deadline Aug 5, 2025; LBA Oct 1, 2025